Anaemia management and mortality risk in newly visiting patients with chronic kidney disease in Japan: The CKD-ROUTE study

作者：Iimori Soichiro; Naito Shotaro; Noda Yumi; Nishida Hidenori; Kihira Hiromi; Yui Naofumi; Okado Tomokazu; Sasaki Sei; Uchida Shinichi; Rai Tatemitsu^*

来源：Nephrology, 2015, 20(9): 601-608.

DOI：10.1111/nep.12493

• anaemia
• cardiovascular disease
• chronic kidney disease
• iron deficiency
• mortality

AimTo investigate the association between iron deficiency anaemia and mortality risk and assess the changes in anaemia and iron status after primary management by a nephrologist.
MethodsIn this prospective cohort study, we stratified 951 non-dialysis chronic kidney disease (CKD) G2-G5 patients newly visiting 16 nephrology centres into four groups according to the presence of anaemia with or without iron deficiency. All-cause mortality, cardiovascular (CV)-related mortality, and a change in anaemia and iron status after specialized primary care were the endpoints evaluated.
ResultsDuring a median follow-up time of 19 months, the number of all-cause deaths and CV-related deaths were 56 and 26, respectively. Compared with the control group, the groups with isolated anaemia and iron deficiency anaemia had significantly higher all-cause mortalities (isolated anaemia: hazard ratio (HR), 3.37; 95% confidence intervals (CI), 1.76-6.44; iron deficiency anaemia: HR, 3.11; 95% CI, 1.21-8.01) and CV-related mortalities (isolated anaemia: HR, 3.64; 95% CI, 1.36-9.73; iron deficiency anaemia: HR, 3.86; 95% CI, 1.11-13.41). In the isolated anaemia group, erythropoietin-stimulating agent (ESA) prescriptions significantly increased to approximately 70%. However, in patients with both anaemia and iron deficiency, iron prescriptions only increased to 48.1%.
ConclusionsIron deficiency anaemia and isolated anaemia were associated with all-cause and CV-related mortality. The absence of relative increase in iron prescriptions suggests that iron deficiency should be accurately assessed and iron supplementation should be appropriately used to manage anaemia in non-dialysis patients with CKD.
Summary at a Glance This interesting paper demonstrates the association between anaemia, iron deficiency and increased mortality (both cardiovascular and all-cause mortality) in a cohort of Japanese people with CKD. While the prescription of ESAs increased significantly in a 6-month period, the iron replacement seemed to be less so, suggesting a potential opportunity for future clinical intervention.

• 出版日期2015-9